Ackaert et al review the immunogenicity risk profile of two VHHs from Phase II clinical trials, examining pre-existing ADAs and comparing to 3 months post-administration.
Review: Immunogenicity Risk Profile of Nanobodies
read more
Technical Resources
A selection of technical resources.
Neurodegenerative Diseases
The advantages of VHH in Neurodegenerative Diseases.
Whitepaper: Clinical landscape for VHHs in immunotherapies
This whitepaper summarises the clinical and research landscape for CAR-T and T-cell engaging antibody therapies and show how single domain VHH antibodies can be applied to optimise the next generation of these important new therapeutic modalities.